目的 觀察仙蟾片聯(lián)合GP化療方案治療老年中晚期非小細(xì)胞肺癌的臨床療效。方法 選取延安大學(xué)附屬醫(yī)院2014年5月-2016年5月收治的老年中晚期NSCLC患者114例，隨機(jī)分為對(duì)照組和治療組，每組各57例。對(duì)照組患者在第1、8天靜脈注射注射用鹽酸吉西他濱，1 g/（m²·d）；同時(shí)于第1~5天靜脈注射順鉑氯化鈉注射液，20 mg/（m²·d）。治療組在對(duì)照組的基礎(chǔ)上口服仙蟾片，4片/次，3次/d。兩組患者連續(xù)治療4個(gè)療程，每個(gè)療程21 d。評(píng)價(jià)兩組患者臨床療效，同時(shí)比較治療前后兩組患者免疫功能指標(biāo)、血清神經(jīng)特異性烯醇化酶（NSE）、癌胚抗原（CEA）、細(xì)胞角蛋白19片段（CYFRA21-1）和鱗狀上皮細(xì)胞癌抗原（SCC）水平以及不良反應(yīng)情況。結(jié)果 治療后，對(duì)照組的客觀緩解率（ORR）和臨床獲益率（CBR）分別為61.40%、82.46%，治療組的ORR和CBR分別為77.19%、85.96%，兩組ORR比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，對(duì)照組IgG、IgA、CD³⁺、CD⁴⁺和CD⁸⁺等免疫功能指標(biāo)顯著降低，而治療組上述免疫功能指標(biāo)水平則明顯增高，且均明顯高于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者血清NSE、CEA、CYFRA21-1和SCC水平均明顯降低（P<0.05）；且治療組的水平明顯低于對(duì)照組（P<0.05）。治療組不良反應(yīng)發(fā)生率均明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 仙蟾片聯(lián)合GP化療方案可有效提高老年中晚期非小細(xì)胞肺癌患者免疫功能，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To study the clinical efficacy of Xianchan Tablets combined with GP chemotherapy in treatment of elderly advanced non-small cell lung cancer. Methods Patients (114 cases) with advanced non-small cell lung cancer in Yan'an University Affiliated Hospital from May 2014 to May 2016 were randomly divided into control and treatment groups, and each group had 57 cases. Patients in the control group were iv administered with Gemcitabine Hydrochloride Injection at first and eighth day, 1 g/(m²·d). And at the same time, they were iv administered with Cisplation and Sodium Chloride Injection from the first to the fifth day, 20 mg/(m²·d). Patients in the treatment group were po administered with Xianchan Tablets on the basis of the control group, 4 tablets/time, three times daily. Patients in two groups were treated for 4 courses of treatment, and each course was 21 d. After treatment, the clinical efficacy was evaluated, and the immune function indexes, serum NSE, CEA, CYFRA21-1, and SCC levels, and adverse actions in two groups before and after treatment were compared. Results After treatment, the ORR and CBR in the control group were 61.40% and 82.46%, the ORR and CBR in the treatment group were 77.19% and 85.96%, and there were differences in ORR between two groups (P<0.05). After treatment, the IgG, IgA, CD³⁺, CD⁴⁺, and CD⁸⁺ level in the control group was significantly decreased, and the levels of immune function indexes in the treatment group were obviously increased and higher than those in the control group, with significant difference between two groups (P<0.05). After treatment, the serum NSE, CEA, CYFRA21-1, and SCC level in two groups was significantly decreased (P<0.05). And the serum level in the treatment group was obviously lower than that the control group (P<0.05). The incidence of adverse reactions in the treatment group was significantly lower than that in the control group, with significant difference between two groups (P<0.05). Conclusion Xianchan Tablets combined with GP chemotherapy can promote the immune function in treatment of advanced non-small cell lung cancer in elderly, which has a certain clinical application value.